Get AI Briefings, Transcripts & Alerts on Local & National Government Meetings — Forever.
Committee backs study and narrow path for supervised psychedelics clinical trials
Loading...
Summary
The committee recommended HB1693 for future legislation to permit narrowly defined, medically supervised clinical trials and research on certain Schedule I psychedelics; members stressed the research should be limited and supervised within medical settings.
The committee recommended HB1693, which would permit narrowly tailored clinical research and supervised therapeutic use of specific psychedelics, emphasizing medical oversight and limits to protect patients.
Representative Leon and others noted expanding clinical evidence and FDA 'breakthrough therapy' designations for certain compounds and said the state should not bar controlled clinical trials. Members emphasized the distinction between recreational legalization and supervised research: the bill as introduced was criticized for being too broad and potentially creating unnecessary bureaucracy, but the committee supported narrowly enabling medical research so patients need not travel out of state for approved clinical trials.
Representative Leon said New Hampshire law currently prevents clinical trials with Schedule I drugs in the state and urged a limited, supervised pathway. Several members — including Representative Weber and Representative Boppall — stressed care in drafting to avoid creating a broad regulatory regime and to limit any new authority to clinical or IRB‑approved research.
Motion to recommend future legislation passed; committee asked sponsors to draft narrow language enabling supervised clinical trials and to coordinate with medical institutions and federal regulatory pathways.
This article quotes committee members and summarizes their stated positions from committee proceedings.
